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Abstract
Background: Missing data on tumour stage information is a common problem in population-based cancer
registries. Statistical analyses on the level of tumour stage may be biased, if no adequate method for handling of
missing data is applied. In order to determine a useful way to treat missing data on tumour stage, we examined
different imputation models for multiple imputation with chained equations for analysing the stage-specific
numbers of cases of malignant melanoma and female breast cancer.
Methods: This analysis was based on the malignant melanoma data set and the female breast cancer data set of
the cancer registry Schleswig-Holstein, Germany. The cases with complete tumour stage information were
extracted and their stage information partly removed according to a MAR missingness-pattern, resulting in five
simulated data sets for each cancer entity. The missing tumour stage values were then treated with multiple
imputation with chained equations, using polytomous regression, predictive mean matching, random forests and
proportional sampling as imputation models. The estimated tumour stages, stage-specific numbers of cases and
survival curves after multiple imputation were compared to the observed ones.
Results: The amount of missing values for malignant melanoma was too high to estimate a reasonable number of
cases for each UICC stage. However, multiple imputation of missing stage values led to stage-specific numbers of
cases of T-stage for malignant melanoma as well as T- and UICC-stage for breast cancer close to the observed
numbers of cases. The observed tumour stages on the individual level, the stage-specific numbers of cases and the
observed survival curves were best met with polytomous regression or predictive mean matching but not with
random forest or proportional sampling as imputation models.
Conclusions: This limited simulation study indicates that multiple imputation with chained equations is an
appropriate technique for dealing with missing information on tumour stage in population-based cancer registries,
if the amount of unstaged cases is on a reasonable level.
Background
An important task of population-based cancer registra-
tion is to assess the effectiveness of early detection pro-
grammes such as mammography screening. Time trend
analysis of cancer incidence is an important indicator in
such an evaluation and is often conducted. Time trend
analysis of tumour stage-specific incidence is more
appropriate, however less frequently applied [1-3]. A
reduction in incidence of tumours with a poor prognosis
might indicate a future reduction in mortality. Complete
stage information is crucial for such analyses. Missing
values for stage information might bias such a stage-spe-
cific analysis, especially when the missingness-pattern
changes over time. A cancer registry may have a very
complete case registration, yet still have missing infor-
mation in important parameters, such as tumour size or
lymph node status, remains an almost common phe-
nomenon in population-based cancer registration. The
percentage of unknown stages can vary considerably
between different cancer entities or cancer registries.
Concerning melanoma and breast cancer, the federal
cancer registries in Germany report the following per-
centages of unknown T-stage (tumour size according to
TNM staging system [4]) between 10-20% [5,6] and of
unknown UICC-stage [7] between 20-40% [8,9]. There
are several reasons for this, one being that tumour stage
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fore, if the case is reported to the registry without addi-
tional notification, e.g. from the physician or from the
pathologists, stage information is lost. Further, some
cancer cases are only reported by a pathologist. These
notifications - in general - do not provide any informa-
tion on lymph node status or metastasis.
Concerning statistical analyses on the level of tumour
stages, three more or less common approaches for deal-
ing with missing stage data can be found: 1. ad-hoc
missing data methods, such as omitting all cases with
missing information [10-12] or analysing them as a
separate group [13], 2. distributing all cases with
unknown stage proportionally to the known stages [14]
and 3. using multiple imputation [15,16].
The first approach is widely known to produce biased
results [17,18].
The second approach yields valid population-based
analyses on tumour stage-specific incidence if the pre-
condition of equal tumour stage distributions among the
cases with unknown T-stage and the cases with known
T-stage is met. If this is not the case, the results will be
biased. Additionally, analysis on the individual level is
not possible with this method. Therefore, the missing
values in tumour stage should be handled with an
appropriate statistical method (such as approach 3)
before calculating the stage-specific incidence rates to
reduce the expected bias.
The following limited simulation analysis is aimed at
determining a feasible method for imputation of missing
stage information in empirical cancer registry data sets.
We used cancer registry data for female breast cancer (a
tumour site with only few missing values) and data for
malignant melanoma (a tumour site with a high propor-
tion of missing data). The cases with complete stage
information were used to derive data sets with simulated
missing stage information. We then analysed the indivi-
dual stage estimations, the stage-specific numbers of
cases and the stage-specific survival curves after treat-
ment with different variants of multiple imputation.
Methods
Databases
Malignant melanoma data (men and women, ICD-10
C43 excl. sarcomas) and breast cancer data (women;
ICD-10 C50) gathered by the cancer registry Schleswig-
Holstein in Germany between 2000 and 2008 was used
for the following analysis. All DCO (death certificate
only) cases were excluded from the analysis.
The cancer registry records data on tumour size (T-
stage), involvement of lymph nodes (N-stage) and metas-
tases (M-stage) according to the TNM-classification (see
additional file 1: TNM-definition for breast cancer and
malignant melanoma) [4,19]. TNM-stages can be
combined to one prognostic classifier, using the UICC-
classification (see additional file 2: UICC-definition) [7].
The T-classification as well as the UICC-classification
consists of four main categories, with stage I having a
good survival prognosis and stage IV a poor prognosis.
Imputation of missing stage information
Our analysis consists of six main steps:
1. Selection of variables
2. Simulation of five breast cancer data sets and five
malignant melanoma data sets
3. Specification of the imputation models
4. Creation of ten complete data sets out of each
simulated data set using multiple imputation
5. Statistical analysis and model evaluation
6. Sensitivity analysis for malignant melanoma
1. Selection of variables
Available clinically relevant variables, potentially related
to stage information, were selected: sex, age at diagnosis,
morphology, topography, grading, operation (yes/no),
radiation therapy (yes/no), chemotherapy (yes/no), hor-
mone therapy (yes/no), survival time and censoring.
Additionally, each of the T-stage, N-stage and M-stage
is associated with the two others, accordingly.
In order to take minor changes in the classification
system over time and other possible temporal changes
into account, year of diagnosis was also included into
the analysis. As the breast cancer analysis excludes men,
the variable sex was removed. No malignant melanoma
patient received hormone therapy, so this variable was
omitted for this data set.
Most categories in the variable morphology of the
tumour had small entries. Thus, only categories affecting
at least 1% of all patients were used. The other cate-
gories were pooled - with the not otherwise specified
(NOS) - into one category. Topography of the tumour
was treated analogously.
Most predictor variables have missing values (Table 1).
This will be addressed by the multiple imputation
method.
2. Simulation of a breast cancer data set and a malignant
melanoma data set
Conducting the multiple imputation methods on a
simulated data set enables us to judge the quality of the
results and to make a significant comparison between
the different methods, because the true results are
known. Although a proper simulation study [20] could
give higher evidence, we decided to restrict the analysis
to a very small simulation study with two scenarios
(female breast cancer and malignant melanoma), one
data generation process (described below) and five simu-
lated data sets each, as this seemed to be a sufficient
approach in recognising the possible methods and deter-
mining which of these produce acceptable results.
Eisemann et al. BMC Medical Research Methodology 2011, 11:129
http://www.biomedcentral.com/1471-2288/11/129
Page 2 of 13Table 1 Description of the observed and the simulated data sets for breast cancer and malignant melanoma patients
Breast cancer data set Malignant melanoma data set
Observed Simulated* Observed Simulated*
Number of cases 21,428 17,162 5,520 1,685
Sex (in %) Female 100 100 45.8 45.1
Male 0 0 54.2 54.9
Age Median
(1
st and 3
rd Quartile)
62.0
(53.0; 71.0)
61.0
(52.0; 69.0)
61.0
(45.0; 70.2)
59.0
(43.0; 68.0)
T-stage (in %) 1 47.3 49.2 36.9 36.9
2 34.0 34.3 11.8 12.4
3 5.5 5.1 8.0 7.6
4 7.3 5.7 4.7 4.4
Unknown 6.0 5.7 38.6 38.7
N-stage (in %) 0 53.4 55.1 29.5 32.5
1 25.4 25.2 1.7 1.4
2 6.1 5.9 0.6 0.4
3 3.7 3.5 0.2 0.1
Unknown 11.4 10.3 67.9 65.6
M-stage (in %) 0 77.9 80.8 31.0 33.5
1 5.6 3.7 2.2 0.7
Unknown 16.5 15.4 66.8 65.8
UICC-stage (in %) I 32.0 29.7 23.9 7.4
II 33.2 30.0 3.3 0.7
III 11.4 10.4 2.8 0.8
IV 5.6 3.7 0.5 0.7
Unknown 17.8 26.1 69.5 90.4
Survival time (days) Median
(1
st and 3
rd Quartile)
1279
(549; 2161)
1279
(580; 2130)
1552
(700; 2253)
1765
(975; 2557)
Censoring (in %) Censored 84.6 88.5 88.1 90.5
Year of diagnosis 2000 10.2 9.7 10.8 15.1
2001 10.7 10.2 11.5 14.4
2002 11.1 10.6 10.0 10.9
2003 10.8 10.9 14.3 12.2
2004 10.7 10.7 12.8 14.6
2005 10.7 10.9 10.7 8.9
2006 11.5 11.6 10.0 10.8
2007 11.6 12.1 9.7 5.0
2008 12.7 13.4 10.3 8.1
Grading (in %) 1 10.6 10.6 3.4 5.7
2 54.2 53.7 0.3 0.2
3 30.0 30.1 0.2 0.2
4 0.2 0.1 < 0.1 0.1
Unknown 5.0 5.5 96.1 93.8
Radiotherapy (in %) Yes 66.4 80.2 1.4 0.5
no 17.8 15.3 52.2 64.5
Unknown 15.8 4.5 46.4 35.0
Chemotherapy (in %) Yes 46.1 47.9 1.8 1.4
No 37.4 36.7 51.8 63.9
Unknown 16.6 15.5 46.5 34.8
Hormone therapy (in %) Yes 60.6 62.3 0.0 0.0
No 19.1 18.1
Unknown 20.3 19.6
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the variables as close as possible. Rather than simulating
the data set by assuming a multivariate normal distribu-
tion of the - if necessary, transformed - variables, which
would involve a certain degree of abstraction, we gener-
ated a data set using the original data set itself as the
data basis: The observed female breast cancer data set D
had approximately 21,500 cases of which 80% had no
missing value in any of the variables T-, N- or M-stage.
These cases were used as the observed values for the
simulated data set S. We assumed that the missingness-
pattern of stage depends mostly on age at diagnosis, sur-
vival time, censoring and the interaction between survi-
val time and censoring. These variables were complete
in D. A logistic regression model was fitted for each
variable with missing values, with age at diagnosis, survi-
val time, censoring and the interaction between survival
time and censoring as independent variables. These
models could now predict the probability of any value
in S to be missing. Every value in S was deleted ran-
domly, depending on its individual missingness-prob-
ability; a value with a high probability of missingness
was therefore more probable to be deleted, but did not
necessarily have to be deleted. The resulting data set
was the simulated data set S.
The generation of missing values depended on a ran-
dom starting value. Changing the random starting value
would have produced a different simulated data set,
which might have resulted in different conclusions
about the imputation methods. To avoid such biases, we
simulated a total of five data sets and obtained 50 com-
pleted data sets for each cancer entity and each variant
of multiple imputation. The missingness-pattern was
independent among the five data sets, but all imputation
methods were conducted on the same five data sets. We
used the default random number generator of R, “Mers-
enne-Twister”, with five different starting seeds.
The observed malignant melanoma data set consisted
of about 5,500 cases, of which 30% had complete T-, N-
and M-stage information. The simulated data set was
generated in the same way as described above.
3. Specification of the imputation models
Multiple imputation with chained equations [21] was
used. Four scenarios with different imputation models
were compared:
(1) Polytomous logistic regression is applicable for
categorial data and may be used for the T- and N-
stages. However, there were only two M-stages, hence
the polytomous logistic regression reduced to dichoto-
mous logistic regression. The imputations of the missing
values in the following four predictor variables morphol-
ogy, radiation therapy, chemotherapy and hormone ther-
apy were randomly sampled from the observed values.
(2) Predictive mean matching is a linear regression, in
which the predicted value is substituted for the closest
observed value. In our case, this yielded a value of 1, 2,
3 or 4 for T and of 0, 1, 2 or 3 for N. This method is
valid for data on an ordinal scale. As for M-stage,
dichotomous logistic regression was used as in scenario
1. The missing values in the predictor variables
Table 1 Description of the observed and the simulated data sets for breast cancer and malignant melanoma patients
(Continued)
Morphology (in %) Infiltrating duct carcinoma 69.0 70.6
Lobular carcinoma 12.3 11.9
Infiltrating duct and lobular carcinoma 7.4 7.9
Nodular melanoma 12.4 13.6
Lentigo maligna melanoma 5.3 5.1
Superficial spreading melanoma 41.4 48.4
Others and NOS 10.5 9.6 41.0 32.8
Topography (in %) Central portion of breast 5.3 5.1
Upper-inner quadrant of breast 9.3 9.6
Lower-inner quadrant of breast 4.6 4.7
Upper-outer quadrant of breast 35.7 36.3
Lower-outer quadrant of breast 6.3 6.3
Axillary tail of breast 0.2 0.1
Overlapping lesion of breast 8.9 8.2
Trunc 32.2 35.9
Extremity 46.7 50.1
Head/Neck 13.5 11.3
NOS 29.9 29.7 7.6 2.7
* For T-, N-, M- and UICC-stage the mean frequencies of the five simulated data sets are provided. The other variables distributions are identical in all five data
sets.
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mone therapy were treated as in scenario 1.
(3) The third scenario consisted of random forests
[22] for T, N and M. Modern machine learning techni-
ques are often superior to classical regression models if
the modelling is complex, for example if interactions
and nonlinear relations are involved [23]. The imputa-
tion models based on logistic regression and predictive
mean matching included the interaction between survi-
val time and censoring in their set of predictor variables,
because a short survival time must be interpreted differ-
ently for a deceased person than for someone still alive,
having only a short follow-up time. No interaction term
was needed in the random forest because this method
can internally model flexible interactions. The missing
values in morphology, radiation therapy, chemotherapy
and hormone therapy were treated as in scenario 1.
(4) The customary approach was to sample the miss-
ing tumour stage values from the observed stages, yield-
ing a proportional distribution. To make the results
comparable to the results from approach (1) to (3), mul-
tiple imputation was used rather than single imputation.
One assumption of multiple imputation is that the
missing values are missing at random (MAR), e.g. the
absence of a particular item is only dependent on other
observable variables and not on unobservable para-
meters, nor the value of the item itself [23]. We
included 13 predictors in the imputation models, which
made the MAR assumption more plausible.
4. Creation of ten complete data sets out of each simulated
data sets using multiple imputation
Ten completed data sets were generated for each simu-
lated data set for both cancer entities, using the four
imputation scenarios introduced above, which is usually
sufficient [24]. Gibbs sampling with ten iterations was
used to ensure model convergence [25].
5. Statistical analysis and model evaluation
The basic quality of the imputations was measured by
the concordance of the stage predictions with their
observed values and the extent of dislocation.
We then calculated T- and UICC-stage-specific num-
bers of cases based on the ten completed simulated data
sets and compared them to the observed stage-specific
numbers of cases. The numbers of cases and their stan-
dard deviations were calculated according to the rules
for combining complete-data inferences [26]. The mean
absolute deviation (MAD) aggregated the information
on differences between the predicted and the observed
stage distributions for comparison of the different
methods.
Finally, we plotted Kaplan-Meier survival curves. As
T- and UICC-stages are prognosis groups, the observed
and the predicted stage-specific survival curves should
be similar. The differences were examined with log-rank
tests for each stage. The log-rank test statistics of all
imputed data sets were summed up to provide a mea-
sure for the total difference and to indicate the best
imputation model.
6. Sensitivity analyses for malignant melanoma
Although ten imputations should generally suffice for
data with a modest amount of 10-30% missingness, the
malignant melanoma with 39% missing T-stages (38% in
the simulated data set) and 70% missing UICC-stages
(91% in the simulated data set) may require more impu-
tations. It must be kept in mind, that a UICC-stage can
a l r e a d yb em i s s i n gi fo n l yo n eo ft h et h r e es t a g e s( T ,N ,
M) is missing. Although a percentage of 91% of the
UICC-stages was missing, ‘only’ 56% of the values needed
for the calculation of the UICC-stage were missing.
We repeated the analysis for malignant melanoma
with 25 imputations and 50, rather than ten, iterations.
Software
All statistical analyses were done in R 2.11.1 [27] using
the packages mice [21], survival [28] and randomForest
[29].
Descriptive statistics
The percentages in the individual variable categories are
given for the description of the data. The median and
the first and third quartiles are shown for age and survi-
val time.
Results
Missing information
There were 21,428 incident cases of female breast can-
cer in Schleswig-Holstein between 2000 and 2008. Six
percent of the cases had no information on the T-stage,
11% had missing values in the N-stage and 16% in the
M-stage. Only 17,162 (80%) cases had valid information
on all three parameters.
In the same time period 5,520 cases of malignant mel-
anoma were registered in Schleswig-Holstein. The per-
centage of missing values was higher than in breast
cancer: 39% in T, 68% in N and 67% in M. The stage
information was complete for 1,685 cases (30%). Table 1
shows the most important variables and their distribu-
tions including the number of missing values.
Simulated data sets
The simulated data sets based on the cases with com-
plete T-, N- and M-stage were similar to the original
data sets for the relevant variables (Table 1). The only
exceptions were a higher percentage of missing values
for UICC-stage (27% versus 18% for breast cancer, 91%
versus 70% for malignant melanoma) and a longer med-
ian survival time for malignant melanoma (1765 versus
1552 days).
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stage in the original data sets are referred to as
“observed values”.
Accuracy of the imputations on individual level
T a b l e2s h o w st h ec o n c o r d a n c er a t eo fi m p u t e da n d
observed T- and UICC-stages. Polytomous regression
and predictive mean matching always yielded the highest
concordance rate: approximately 48% of all imputations
matched the observed T-stage value and approximately
80% of all imputation matched the observed UICC-stage
for both cancer entities. These concordance rates were
higher than can be achieved by chance, as the lower
concordance rates rendered by proportional sampling
indicate.
Dislocations by three stages, i.e. a T1 (UICC I)
imputed as T4 (UICC IV) or vice versa, occurred in less
than 5% of all imputations for polytomous regression
and predictive mean matching.
Estimations of the stage-specific numbers of cases
Table 3 displays the observed and the predicted case
numbers for T- and UICC-stage after multiple imputa-
tion with the different scenarios. For example, there
were 8,909 breast cancer cases in T1-stage in the
observed data set. After multiple imputation of missing
values in the simulated data set, a number of 8,903.2
was predicted by the polytomous regression approach.
Polytomous regression and predictive mean matching
for multiple imputation of missing T-stage had the
smallest deviations from the observed case numbers for
breast cancer. The best results for malignant melanoma
were again achieved by these approaches and also by
proportional sampling. Although the percentage of miss-
ing values was substantially higher for malignant mela-
noma, the results for T-stage were comparable for both
breast cancer and melanoma.
Polytomous regression and predictive mean matching
were also showing similar results for UICC-stage, how-
ever the proportional approach was even closer to the
observed stage-specific numbers of cases for malignant
melanoma.
The random forest scenario was always less accurate
than the estimations by the other scenarios and had the
largest standard deviations.
Survival curve estimations
The sum of log-rank test statistics over all stages and
imputations in Figures 1, 2, 3 and 4 indicate that the
survival curves after multiple imputation with polyto-
mous regression or predictive mean matching were clo-
ser to the observed survival curves than those after
multiple imputation with random forests or proportional
imputation. The log-rank statistics for UICC-stage for
malignant melanoma were considerably higher than for
T-stage or breast cancer (332.3 versus 80.8, 11.7 or 47.9
for polytomous regression).
Sensitivity analyses
The results for malignant melanoma after multiple
imputations with 25 imputations and 50 iterations
altered only marginally and are not shown here. The
greatest changes occurred for the random forest sce-
nario, which can be explained by the large variance in
all its estimations. Convergence of the multiple imputa-
tion algorithms was usually achieved very soon, i.e. even
Table 2 Concordance rates of imputed with observed T- and UICC-stages for breast cancer and malignant melanoma
Breast cancer Malignant melanoma
PR (in %) PMM (in %) RF (in %) Prop (in %) PR (in %) PMM (in %) RF (in %) Prop (in %)
T-stage
Concordance 48.7 48.0 31.4 39.4 47.7 47.2 40.6 42.5
Dislocation by 1 stage 37.8 38.4 55.4 41.5 32.0 32.3 30.8 31.0
Dislocation by 2 stages 10.1 10.3 8.2 11.4 15.4 15.5 19.9 18.1
Dislocation by 3 stages 3.4 3.4 5.0 7.7 4.9 5.0 8.7 8.4
UICC-stage
Concordance 79.5 79.1 58.8 74.2 80.6 80.8 77.9 79.5
Dislocation by 1 stage 17.3 17.6 25.0 19.9 11.1 10.8 13.3 11.5
Dislocation by 2 stages 2.9 2.9 14.2 4.8 6.2 5.7 8.1 7.4
Dislocation by 3 stages 0.3 0.3 1.9 1.1 2.1 2.7 0.6 1.6
PR Polytomous regression
PMM Predictive mean matching
RF Random forests
Prop Proportional sampling
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random forest approach often did not converge at all.
Discussion
Population-based cancer registry data is an important
source for the evaluation of early detection programmes.
Stage-specific analysis of incidence is especially crucial.
A decrease in incidence of cancer with poor prognosis
might be a strong indicator for future mortality reduc-
tion [1,2]. However, it is almost impossible to collect all
data without missing information on the tumour stage,
even if the cancer registry has complete registration.
Missing data on tumour stage poses as a serious pro-
blem in the evaluation of early detection programmes.
Completing the data set by an active follow-back, such
as repeated record inspection, physician interview or
other strategies is desirable, would, however, involve
high costs and be very time consuming. Thus,
appropriate alternatives in handling the unknown infor-
mation in the cancer registry data set should be used. In
this analysis, different variants of multiple imputation
were studied, with respect to their feasibility and appro-
priateness for the imputation of missing values in
tumour stages, limiting our analysis to one cancer entity
with a high number of cases with missing tumour stage
information and one cancer entity with only few missing
tumour stage data.
Multiple Imputation
A flexible and common approach of dealing with miss-
ing values is multiple imputation [15-17,30]. Multiple
imputation with chained equations works as follows: for
each variable with missing values an individual imputa-
tion model is fitted. The predictor variables are related
to the missingness and/or to the value of the respective
variable. The incomplete data set is completed by
Table 3 Observed and with different multiple imputation methods predicted T- and UICC-stage-specific numbers of
cases for breast cancer and malignant melanoma
Breast cancer Malignant melanoma
Observed PR PMM RF Prop Observed PR PMM RF Prop
T-stage
1 N 8,909.0 8,903.2 8,903.5 8,788.2 8,950.5 1,017.0 1,009.8 1,014.5 962.3 1,013.7
SD 94.4 96.5 96.5 108.6 97.6 31.9 37.4 38.2 207.2 37.3
2 N 6,235.0 6,236.7 6,239.5 6,394.9 6,228.6 338.0 341.8 340.2 332.7 341.2
SD 79.0 82.6 83.0 83.3 84.1 18.4 26.8 29.9 116.8 25.7
3 N 944.0 944.5 946.7 944.9 936.4 214.0 212.1 209 242.1 209.0
SD 30.7 33.0 33.3 33.8 32.7 14.6 18.7 19.2 129.6 17.7
4 N 1,074.0 1,077.6 1,072.3 1,034.1 1,046.5 116.0 121.3 121.3 147.9 121.1
SD 32.8 36.3 35.9 57.3 35.3 10.8 13.6 15.5 121.8 16.6
MAD 59.8 57.8 341.9 104.1 48.4 55.4 409.2 49.2
SD 23.3 30.1 97.5 30.4 23.5 26.1 242.6 20.3
UICC-stage
I N 6,859.0 6,865.7 6,856.7 6,096.1 6,642 1,321.0 1,269.8 1,276.8 1,213.7 1,267.8
SD 82.8 85.4 85.4 261.0 85.5 36.3 39.5 41.1 222.0 41.7
II N 7,123.0 7,119.5 7,133.9 6,891.8 7,295.9 216.0 204.4 208.4 271.1 238.6
SD 84.4 87.5 87.4 425.7 88.8 14.7 24.7 24.8 143.1 21.5
III N 2,371.0 2,361.7 2,351.9 3,206.1 2,462.6 122.0 149.9 124.5 173.4 143.6
SD 48.7 53.2 53.0 381.6 58.4 11.0 21.2 22.9 199.8 17.5
IV N 809.0 815.1 819.5 968.0 761.5 26.0 60.9 75.2 26.9 35.0
SD 28.4 31.3 31.6 593.6 32.2 5.1 14.8 18.4 8.6 9.5
MAD 68.5 72.7 2182.4 528.8 133.9 126.9 344.4 107.5
SD 25.8 30.9 988.5 47.2 28.1 35.6 411.8 41.5
N Number of cases
SD Standard deviation
PR Polytomous regression
PMM Predictive mean matching
RF Random forests
Prop Proportional sampling
MAD Mean absolute difference between the predicted number of caces in all 50 imputations and the observed number of cases.
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responding imputation model. This is done m times,
generating m completed data sets. Now the statistical
analysis of interest is performed with each data set sepa-
rately. Finally the m results are pooled to one result
[31]. The application of multiple imputation is more
complex than the use of other missing-data-approaches
[32].
There are two main advantages of multiple imputa-
tion. First, in contrast to complete case analysis, all
information in the data set is used in the analysis and
the results are less likely to be biased. Second, missing
v a l u e sc a no n l yb ei m p u t e dw i t hs o m ed e g r e eo fu n c e r -
tainty. In contrast to single imputation methods this
uncertainty is reflected by the variability of the m results
[33,34].
Difference between T- and UICC-stage predictions
Only about 20% of the imputed values for UICC-stage
are different from the observed values, while about
50% of the T-stage imputations are dislocated by at
least one stage. It has to be taken into account that
UICC-stage is generated fromt h et h r e es t a g ev a r i a b l e s
T, N and M and in many cases only one or two of
them are missing.
Although the UICC-stage imputations for malignant
melanoma correspond so well to the observed values on
the individual level, the predictions of the stage-specific
numbers of cases and survival curves were not accurate.
This is due to the fact that the percentage of missing
values is much higher in malignant melanoma cases and
therefore a percentage of 50% dislocated imputed stage
values has a greater impact in the total data set.
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Figure 1 T-stage-specific survival curves for female breast cancer. The predicted survival curves are based on the 50 completed data sets.
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Page 8 of 13Choice of the most appropriate imputation model
Machine learning techniques have been reported to pro-
duce better results than other classification models in
situations with complex relations such as interactions or
nonlinear relations [23,35]. Thus, we used random for-
ests as an imputation model in addition to the two
methods, which were already implemented in the mice-
package in R (polytomous regression and predictive
mean matching) to compare them to proportional
sampling.
Overall, the imputation scenario based on polytomous
regression seems to yield the best results. Imputed stage
values are closest to the observed values; the difference
of stage-specific numbers of cases to the observed data
is smallest and the stage-specific survival curves fit best
to the observed ones.
The predictive mean matching scenario yields results
nearly as accurate as those by polytomous regression. It
has the advantage of a shorter processing time and was
found to be an appropriate method for imputation of
missing values in other studies [36]. An explanation for
the slightly better results of the polytomous regression
might be a nonlinearity of the stages.
Using regression trees as imputation models for multi-
ple imputation was found to be promising elsewhere
[23]. Random forests, which consist of many regression
trees, produce more stable results than a single regres-
sion tree. However, in the context of our study the esti-
mations by the random forest scenario tended to have
very large variances and were the most biased of all four
scenarios. This might be due to convergence problems
in the data completion; random forests are able to
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Figure 2 T-stage-specific survival curves for malignant melanoma. The predicted survival curves are based on the 50 completed data sets.
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Page 9 of 13model complex relations, but if there is a lot of noise in
the data, a random forest fits the model to this noise
a n dt h em o d e lf i t sc a na l t e rt oag r e a te x t e n tf r o mo n e
iteration to the next. A simpler model such as polyto-
mous regression or predictive mean matching seems to
fit our data better.
The amount of missing values for the UICC-stage for
malignant melanoma was too high to permit reasonable
estimations by any of the applied methods. This agrees
with other findings [36], that estimates are biased when
the proportion of missing data exceeds 50%. In this
case, the imputation can be strongly influenced by noise
and produce biased results. In such a situation the pro-
portional sampling approach, which does not depend on
any covariates and cannot be influenced by their noise,
yielded better estimations of the stage-specific numbers
of cases. However, this approach makes the strong and
probably inapplicable assumption that the stage distribu-
t i o ni nt h eu n k n o w ns t a g e si st h es a m ea si nt h e
observed stages. The conventional method of assigning
all cases with unknown stage proportionally to the
known stages - which is equivalent to proportional sam-
pling with only one imputation - has the additional
drawback of single imputation compared to multiple
imputation.
Strengths and limitations
The cancer registry in Schleswig-Holstein has a high
completeness: it is estimated to be almost 100% [37].
Therefore, the only possible source for bias in the stage-
specific numbers of case estimates is a biased imputa-
tion model in the multiple imputation procedure. The
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Figure 3 UICC-stage-specific survival curves for female breast cancer. The predicted survival curves are based on the 50 completed data
sets.
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Page 10 of 13high completeness also reduces the risk of biased impu-
tation models because no significantly different sub-
groups are missing in the model building.
A simulation study has the great advantage of making
the results of the different methods comparable, because
the true results are known.
One limitation of our small simulation study is the
restriction to one scenario for the generation of the
simulated data sets, that is the exclusion of the cases
with missing T-, N- or M-stage from the simulated data
sets. If these cases differ substantially from the other
cases, the results of the analyses are not directly trans-
ferable. The same problem would occur if the real miss-
ingness-pattern differs substantially from the model we
fitted from the original data set and used to generate
the simulated data sets. The greatest difference between
the simulated data set and the original data sets is the
higher amount of missing values in UICC-stage. The
values in T-, N- and M-stage were removed with sepa-
rate models, which lessens the correlation between the
missingness in these three variables. Thus, there were
more cases to fill in, but the same number of missing
values had to be imputed. Another difference occurred
because a disproportionally high number of cases with a
short survival time was omitted from the malignant mel-
a n o m ad a t as e t .T h i si sn o ts e e na sab i a si nt h ed a t a
sets, because the shorter survival time probably only
means a shorter registration time, i.e. less time to get
notifications on T-, N- and M-stage. For the other vari-
ables, the univariate distributions in the simulated data
set did not differ very much from those in the original
data set.
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Page 11 of 13The simulation of each five data sets for both cancer
entities was aimed at controlling the variation of results
due to the random deletion of values, but it is still a
small number of simulations.
A proper simulation study would require additional
scenarios in the design of simulated data sets, a higher
number of simulations and a more detailed reporting of
the results of the simulation study [20]. However, this
limited simulation study appeared to be sufficient at
identifying feasible imputation methods that provide
reasonable results in cancer epidemiology.
Another limitation is that the imputation models do
not take into account that the follow-up period for the
recently diagnosed patients is quite short, which leads to
very short survival times for patients who are alive and
w h om a yh a v eav e r yg o o dp r o g n o s i s .W ea t t e m p t e dt o
address this problem by including an interaction term
for censoring and survival time and employing a random
forest as imputation model, which might be capable of
modelling such complex relations. The inclusion of year
of diagnosis as predictor variable also helped to model
this effect.
Further, the results are restricted to the data on two
cancer entities of one cancer registry.
Conclusions
For statistical analysis of tumour stage information in can-
cer registry data, both on the individual and the aggregated
level, multiple imputation with chained equations using
polytomous regression or predictive mean matching as an
imputation model was in this limited simulation study
found to be an appropriate method for dealing with miss-
ing data in tumour stage. Utilizing one of these methods
should lead to less biased estimates than using a crude
proportional method. Polytomous logistic regression and
also predictive mean matching regression as imputation
models for T-, N- and M-stage yield good estimations on
the individual stage value, thes t a g e - s p e c i f i cn u m b e r so f
cases and the stage-specific survival curves, as long as the
amount of missing values is not too high. In contrast, ran-
dom forests are not recommended because convergence
problems in the multiple imputation were observed, the
results are less close to the observed parameters and have
often large variances.
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